Veeva Systems (VEEV) Jumps 7.4% After Unveiling Falcon AI Platform for Drug Development

Shares of Veeva Systems (NYSE:VEEV) surged 7.4% in afternoon trading on June 2, 2026, after the life sciences cloud software provider introduced Falcon, a new artificial intelligence platform aimed at automating drug development workflows. The company also announced several major global customer commitments. Falcon is designed to streamline tasks for clinical, regulatory, and safety teams within the life sciences industry. Integrated with Veeva’s Development Cloud applications, the platform targets processes such as trial master file document intake and health authority correspondence. The stock remains under pressure, down 15.1% year-to-date and trading at $186.29—39.2% below its 52-week high of $306.22 set in October 2025. The move follows a 3.8% gain four days earlier, when Kindeva adopted Veeva’s Quality Cloud platform to unify its manufacturing operations.